Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Formulation 00B is a topical cutaneous emulsion developed by ISDIN to serve as the vehicle control (placebo) in clinical trials evaluating experimental topical formulations of ciclosporin. Specifically, it was used as the comparator for Formulation 01B (0.5% ciclosporin) and Formulation 02B (1.5% ciclosporin) in a Phase I, randomized, vehicle-controlled study for the treatment of psoriasis vulgaris. As a vehicle, it is designed to match the physical and chemical properties of the active formulations—including the emulsion base and excipients—but lacks the active pharmaceutical ingredient, ciclosporin. This allows for the assessment of the baseline effect of the formulation base and ensures the integrity of double-blinded psoriasis plaque tests.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Formulation 00B.